Questions | Reviews
Before QuotesChimp begin exploring the four major types of personal insurance, let us start with a brief explanation of insurance and why you need it to manage the risks in your life. Understanding this will help you be better prepared when you visit ...
by Chuck in Chuck, 03/06/2014
I would be interested to know the scatistits for those who have known mental health issues, including chronic anxirty and depression, who are currently on IB or ESA and who have recently undergone their capability to work assessment by ATOS who's info...
by Doel in Doel, 01/13/2014
Classification: Antineoplastic, miscellaneous
See Also: See also Antineoplastic Agents.
Action/Kinetics: Is a human interleukin-2 (IL-2) product produced by recombinant DNA technology, The recombinant form differs from natural IL-2 in that aldesleukin is not glycosylated, the molecule has no N-terminal alanine, the molecule has serine substituted for cysteine at amino acid position 125, and the aggregation state of aldesleukin may be different from that of native IL-2. However, aldesleukin possesses the biologic activity of human native IL-2. Drug effects include activation of cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia; the production of cytokines, including tumor necrosis factor, IL-1, and gamma-interferon; and inhibition of tumor growth. The exact mechanism of action of aldesleukin is not known but may induce the proliferation of natural killer and cytotoxic T cells, which recognize and fight tumor-specific antigens located on the surface of malignant cells. High plasma levels reached after a short IV infusion; rapidly distributed to the extravascular, extracellular space. Rapidly cleared from the circulation by both glomerular filtration and peritubular extraction; metabolized in the kidneys with little or no active form excreted through the urine. t 1/2, distribution: 13 min; t 1/2, elimination: 85 min.
Uses: Metastatic renal cell carcinoma in adults 18 years of age and older. Metastatic melanona. Investigational: Kaposi's sarcoma in combination with AZT, metastatic melanoma in combination with low-dose cyclophosphamide, colorectal cancer and non-Hodgkin's lymphoma often in combination with lymphokine-activated killer cells.
Hypersensitivity to IL-2 or any components of the product. Abnormal thallium stress test or pulmonary function tests. Organ allografts. Use in either men or women not practicing effective contraception. Lactation.
Special Concerns: Symptoms may worsen in clients with unrecognized or untreated CNS metastases. Use of medications known to be nephrotoxic or hepatotoxic may further increase toxicity to the kidney and liver caused by aldesleukin. May increase the risk of allograft rejection in transplant clients. Safety and efficacy have not been established in children less than 18 years of age.
Side effects are frequent, often serious, and sometimes fatal. Most clients will experience fever, chills, rigors, pruritus, and GI side effects. The frequency and severity of side effects are usually dose-related and schedule-dependent. Incidence of side effects is greater in PS 1 clients than in PS 0 clients. The side effects listed have an incidence of 1% or greater.
CV: Hypotension (sometimes requiring vasopressor therapy), sinus tachycardia, arrhythmias (atrial, junctional, supraventricular, ventricular), bradycardia, PVCs, premature atrial contractions, myocardial ischemia, MI, cardiac arrest, CHF myocarditis, endocarditis, gangrene, stroke, pericardial effusion, thrombosis. Respiratory: Pulmonary congestion, dyspnea, pulmonary edema, respiratory failure tachypnea, pleural effusion, wheezing, apnea, pneumothorax, hemoptysis. GI: N&V, diarrhea, stomatitis, anorexia, GI bleeding (sometimes requiring surgery), dyspepsia, constipation, intestinal perforation intestinal ileus, pancreatitis. CNS: Changes in mental status (may be an early indication of bacteremia or early bacterial sepsis), dizziness, sensory dysfunction, disorders of special senses (speech, taste, vision), syncope, motor dysfunction, coma, seizure. GU: Oliguria or anuria, proteinuria, hematuria, dysuria, impaired renal function requiring dialysis, urinary retention, urinary frequency. Hepatic: Jaundice, ascites, hepatomegaly. Hematologic: Anemia, thrombocytopenia, leukopenia, coagulation disorders, leukocytosis, eosinophilia. Dermatologic: Pruritus, erythema, rash, dry skin, exfoliative dermatitis, purpura, petechiae, urticaria, alopecia. Musculoskeletal: Arthralgia, myalgia, arthritis, muscle spasm. Electrolyte and other disturbances: Hypomagnesemia, acidosis, hypocalcemia, hypophosphatemia, hypokalemia, hyperuricemia, hypoalbuminemia, hypoproteinemia, hyponatremia, hyperkalemia, alkalosis, hypoglycemia, hyperglycemia, hypocholesterolemia, hypercalcemia, hypernatremia, hyperphosphatemia. Miscellaneous: Fever, chills, pain (abdominal, chest, back), fatigue, malaise, weakness, edema, infection (including the injection site, urinary tract, catheter tip, phlebitis, sepsis), weight gain or weight loss, headache, conjunctivitis, reactions at the injection site, allergic reactions, hypothyroidism.
Laboratory Test Alterations: BUN, bilirubin, serum creatinine, transaminase, alkaline phosphatase. See also Electrolyte and other disturbances under Side Effects.
Overdose Management: Symptoms: See Side Effects. Treatment: Side effects will usually reverse if the drug is stopped, especially because the serum half-life is short. Continuing toxicity is treated symptomatically. Life-threatening side effects have been treated by the IV administration of dexamethasone (which may result in loss of the therapeutic effectiveness of aldesleukin).
How Supplied: Powder for injection: 22 million IU